BDR pharma launches ‘RUCAPARIB’ to treat advanced ovarian & protstate cancers in India

Hyderabad : BDR Pharmaceutical on Thursday launched BDPARIB (RUCAPARIB) to treat advanced ovarian and prostate cancers in India.

BDPARIB is the first affordable generic in the India available in the form of a tablet, with the cost of therapy less expensive than any existing drugs in the market, BDR, which is recognized as a “niche” player in manufacturing of Pharmaceutical APIs and for the renowned new age formulations, said in a release.

RUCAPARIB is an oral, small-molecule inhibitor of poly (ADP-ribose) polymerase (PARP)1, 2, and 3 used as a monotherapy and in conjunction with other anti-cancer agents in several tumor forms, including ovarian and prostate cancers.

It has played a significant role in treating ovarian cancer patients with BRCA mutation (germline or somatic) associated with epithelial ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more chemotherapy.

“BDPARIB was developed to treat patients living with advanced ovarian and prostate cancer with an unmet need. This research’s positive results through the ARIEL3 study & TRITON2 study are highly promising and indicate that the benefits extend beyond the BRCAm population.”

This represents a significant advancement in the treatment of cancer patients in the future, the release said.

Approvals for generics like Rucaparib, a PARP inhibitor, enables us to progress in this emerging era of personalized medicine and eradicate life-threatening diseases”, said Mr.Dharmesh Shah, CMD, BDR Pharma.

The ARIEL3 and TRITON2 study was conducted on 115 patients.

The product is priced at Rs 54,000 (Bottle of 60)for 300 Mg dose and MRP ₹ 45,000 (Bottle of 60) for 200 Mg dose, the release added.